Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Perhexiline is a carnitine palmitoyltransferase 1 (CPT1) and CPT2 inhibitor that was originally developed as an anti-anginal drug in the 1970s.1,2,3 It inhibits rat heart and liver CPT1 (IC50 = 77 and 148 µM, respectively) and rat heart CPT2 (IC50 = 79 µM).1,2 Inhibition of CPT reduces uptake of long-chain fatty acids into the mitochondria, thereby shifting cellular metabolism from β-oxidation to glycolysis. Perhexilin inhibits mTORC1 signaling at 10 µM and induces autophagy ~7-fold at a concentration of 10 µM in MCF-7 cells.4
WARNING This product is not for human or veterinary use.
1. Inhibition of carnitine palmitoyltransferase-
2. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-
3. Perhexiline. Cardiovasc. Drug Rev. 25(1), 76-97 (2007).
4. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 4(9), e7124 (2009).
A precision therapeutic strategy for hexokinase 1-